Evidence map›Paper›PMID 26800973›Full record

ArticleCell stress & chaperones2016

Gypenosides alleviate myocardial ischemia-reperfusion injury via attenuation of oxidative stress and preservation of mitochondrial function in rat heart.

Haijie Yu, Qigang Guan, Liang Guo, Haishan Zhang, Xuefeng Pang, Ying Cheng, Xingang Zhang, Yingxian Sun

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell stress & chaperones, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
4.4field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 65 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Anti-ischemic effect ofF1000Research · 2022
    Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Haijie YuDepartment of Cardiology, The First Affiliated Hospital of China Medical University, Shenyang, 110001, People's Republic of China. haijieyu@126.com.
Qigang GuanDepartment of Cardiology, The First Affiliated Hospital of China Medical University, Shenyang, 110001, People's Republic of China.
Liang GuoDepartment of Cardiology, The First Affiliated Hospital of China Medical University, Shenyang, 110001, People's Republic of China.
Haishan ZhangDepartment of Cardiology, The First Affiliated Hospital of China Medical University, Shenyang, 110001, People's Republic of China.
Xuefeng PangDepartment of Cardiology, The First Affiliated Hospital of China Medical University, Shenyang, 110001, People's Republic of China.
Ying ChengDepartment of Cardiology, The First Affiliated Hospital of China Medical University, Shenyang, 110001, People's Republic of China.
Xingang ZhangDepartment of Cardiology, The First Affiliated Hospital of China Medical University, Shenyang, 110001, People's Republic of China.
Yingxian SunDepartment of Cardiology, The First Affiliated Hospital of China Medical University, Shenyang, 110001, People's Republic of China.
China Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gypenosides (GP) are the predominant components of Gynostemma pentaphyllum, a Chinese herb medicine that has been widely used for the treatment of chronic inflammation, hyperlipidemia, and cardiovascular disease. GP has been demonstrated to exert protective effects on the liver and brain against ischemia-reperfusion (I/R) injury, yet whether it is beneficial to the heart during myocardial I/R is unclear. In this study, we demonstrate that pre-treatment with GP dose-dependently limits infarct size, alleviates I/R-induced pathological changes in the myocardium, and preserves left ventricular function in a rat model of cardiac I/R injury. In addition, GP pre-treatment reduces oxidative stress and protects the intracellular antioxidant machinery in the myocardium. Further, we show that the cardioprotective effect of GP is associated with the preservation of mitochondrial function in the cardiomyocytes, as indicated by ATP level, enzymatic activities of complex I, II, and IV on the mitochondrial respiration chain, and the activity of citrate synthase in the citric acid cycle for energy generation. Moreover, GP maintains mitochondrial membrane integrity and inhibits the release of cytochrome c from the mitochondria to the cytosol. The cytoprotective effect of GP is further confirmed in vitro in H9c2 cardiomyoblast cell line with oxygen-glucose deprivation and reperfusion (OGD/R), and the results indicate that GP protects cell viability, reduces oxidative stress, and preserves mitochondrial function. In conclusion, our study suggests that GP may be of clinical value in cytoprotection during acute myocardial infarction and reperfusion.

Indexed as

AnimalsAntioxidantsApoptosisGynostemmaHumansMembrane Potential, MitochondrialMitochondria, HeartMitochondrial Membrane Transport ProteinsMyocardial InfarctionMyocardial Reperfusion InjuryMyocytes, CardiacOxidative StressPlant ExtractsRatsReactive Oxygen SpeciesAntioxidantsgypenosideMitochondrial Membrane Transport ProteinsPlant ExtractsReactive Oxygen SpeciesCardioprotectionGypenosidesMitochondrial functionMyocardial ischemia-reperfusionOxidative stress

Identifiers

PMID26800973
PMCPMC4837178
OpenAlexW2294520393

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.